Objectives: To investigate the effects of allitridin on human ether-à-go-go-related gene (hERG) channels. Methods: We used whole-cell patch clamping and laser confocal scanning microscopy to evaluate the effects of allitridin on hERG currents and the membrane expression of the hERG protein expressed in HEK 293 cells. Results: The amplitude of IKr showed a concentration-dependent decrease with increasing allitridin concentration. Additionally, alterations in the gating properties of hERG channels were also confirmed. Allitridin does not alter the voltage- and time-dependent activation of hERG channels, the gating properties of hERG channel inactivation over time or the recovery from inactivation, but allitridin does cause alterations in the steady-state inactivation and the deactivation of hERG channels. We further evaluated the influence of allitridin on membrane expression of the hERG protein. Images of allitridin-treated cells showed a reduction in hERG protein on the membrane and retention in the cytoplasm. Conclusions: To the best of our knowledge this is the first study to show that allitridin reduces the IKr current by impairing the trafficking of hERG channels. The results may demonstrate that allitridin could be a promising candidate for the prevention and treatment of arrhythmia-related diseases.

1.
Sanguinetti MC, Tristani-Firouzi M: hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-469.
2.
Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998;74:230-241.
3.
Staudacher I, Schweizer PA, Katus HA, Thomas D: hERG: protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel 2010;13:23-30.
4.
Shukla Y, Kalra N: Cancer chemoprevention with garlic and its constituents. Cancer Lett 2007;247:167-181.
5.
Dorant E, van den Brandt PA, Goldbohm RA, Hermus RJ, Sturmans F: Garlic and its significance for the prevention of cancer in humans: a critical view. Br J Cancer 1993;67:424-429.
6.
Ariga T, Seki T: Antithrombotic and anticancer effects of garlic-derived sulfur compounds: a review. Biofactors 2006;26:93-103.
7.
Ariga T, Oshiba S, Tamada T: Platelet-aggregation inhibitor in garlic. Lancet 1981;1:150-151.
8.
Antony ML, Singh SV: Molecular mechanisms and targets of cancer chemoprevention by garlic-derived bioactive compound diallyl trisulfide. Indian J Exp Biol 2011;49:805-816.
9.
Das I, Saha T: Effect of garlic on lipid peroxidation and antioxidation enzymes in DMBA-induced skin carcinoma. Nutrition 2009;25:459-471.
10.
Chan KC, Yin MC, Chao WJ: Effect of diallyl trisulfide-rich garlic oil on blood coagulation and plasma activity of anticoagulation factors in rats. Food Chem Toxicol 2007;45:502-507.
11.
Allison GL, Lowe GM, Rahman K: Aged garlic extract and its constituents inhibit platelet aggregation through multiple mechanisms. J Nutr 2006;136:782S-788S.
12.
Rahman K, Lowe GM: Garlic and cardiovascular disease: a critical review. J Nutr 2006;136:736S-740S.
13.
Zahid Ashraf M, Hussain ME, Fahim M: Antiatherosclerotic effects of dietary supplementations of garlic and turmeric: restoration of endothelial function in rats. Life Sci 2005;77:837-857.
14.
Bordia A, Verma SK, Srivastava KC: Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1998;58:257-263.
15.
Ahmadi N, Zughaib H, Patel N, Rathod A, Hajsadeghi F, Flores F, Ebrahimi R, Mao S, Budoff M: Relation of changes in coronary artery calcium, bone mineral density measured computed tomography and aged garlic extract (abstract). Circulation 2011;124:A11080.
16.
Deng CY, Rao F, Kuang SJ, Wu SL, Shan ZX, Li XH, Zhou ZL, Lin QX, Liu XY, Yang M, Lin SG, Yu XY: Allitridi inhibits transient outward potassium currents in human atrial myocytes. Clin Exp Pharmacol Physiol 2011;38:323-327.
17.
Zhang A, Sun C, Zhang L, Lv Y, Xue X, Li G, Cui C, Yan GX: L539 fs/47, a truncated mutation of human ether-a-go-go-related gene (hERG), decreases hERG ion channel currents in HEK 293 cells. Clinical and experimental pharmacology & physiology 2013;40:28-36.
18.
Wang X, Li L, Zou A, Tu D, Liao Y: Analysis and analyzing mechanisms of HERG channel kinetics (in Chinese). Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2008;25:1068-1073.
19.
Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H: Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007;4:603-607.
20.
Waldo AL: A perspective on antiarrhythmic drug therapy to treat atrial, fibrillation: there remains an unmet need. Am Heart J 2006;151:771-778.
21.
Dobrev D, Nattel S: New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010;375:1212-1223.
22.
Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, Darley-Usmar VM, Doeller JE, Kraus DW: Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci USA 2007;104:17977-17982.
23.
Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, Zhu YC: The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc Res 2007;76:29-40.
24.
Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, Snyder SH, Wang R: H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ-lyase. Science 2008;322:587-590.
25.
Tang G, Wu L, Wang R: Interaction of hydrogen sulfide with ion channels. Clin Exp Pharmacol Physiol 2010;37:753-763.
26.
Dennis A, Wang L, Wan X, Ficker E: hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 2007;35:1060-1063.
27.
Roden DM: Drug therapy: drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.